Skip to main content
  • Greenselect® Phytosome® (GSP) – New Clinical Study

    About Greenselect® Phytosome® (GSP)

    Greenselect® Phytosome® is a proprietary, caffeine free, catechin extract from green tea formulated with Phytosome® technology. Greenselect® Phytosome® is supported by two independent human studies showing its beneficial effects on weight management and on general health when associated with diet.1,4

    Greenselect® Phytosome® is a light brown powder for use in nutritional supplements with a recommended daily dose of 2x150mg daily doses.

    The uniqueness of Greenselect® Phytosome® lies in its Phytosome® strategy. Its phytochemical profile is delivered in the Phytosome® system, able to optimize the biological absorption of polyphenols normally poorly soluble in both water and organic solvents.

    Pioneering Phytosome® formulation is specifically intended to facilitate dissolution profile and pharmacokinetic of botanical extracts, making Greenselect® Phytosome® so distinctive.

    About the Study

    A new study informs us of new clinical evidence for Greenselect® Phytosome® (GSP), evaluating the efficacy of a 60-day supplementation on adipose tissue dysfunction in overweight or class I obese post-menopausal, sedentary women, was published in December 2022. The study was conducted by the University of Pavia and published in Nutrients (IF: 6.706). 

    Key points of this new study: 

    • Double-blind, placebo-controlled randomized trial
    • 28 overweight or class I obese post-menopausal, sedentary women were randomized into two groups receiving placebo and GSP supplementation 
    • Supplemented subjects received two daily oral doses (before lunch and dinner) of 150mg GSP for 60 days.
    • Primary endpoint metabolic parameters included
      • respiratory quotient (RQ)
      • the percentage of carbohydrates (%CHO)
      • the percentage of fat oxidation (%FAT)
      • resting energy expenditure (REE) 

    Secondary endpoints included

    body composition by dual x-ray absorptiometry (DXA), glucose profile, lipid profile, inflammatory state, liver and kidney function, hormonal status regarding satiety, and status of catecholamines.

    • The enrolled subjects are only women, widening the Indena women’s health portfolio.

    The following are key findings after 60 days of supplementation:

    • The GSP supplemented group showed a statistically significant decrease in RQ, insulin,  homeostatic model assessment (HOMA; measuring insulin resistance andβ-cell function), waist circumference, visceral adipose tissue (VAT), fat mass, %CHO, and CRP (inflammatory marker) when compared to values at baseline. 
    • In the placebo group, a statistically significant decrease was seen in waist circumference, and a statistically significant increase was reported for adiponectin/leptin ratio, compared to values at baseline. 
    • Between the groups, there was a significant change in the following parameters over time: insulin, HOMA, CRP, waist circumference, resting energy expenditure (REE), RQ, %CHO, and %LIP. 

    No serious adverse events were reported, validating the safety and tolerability of GSP for overweight or obese subjects. 

    Overall, the results of this study provide clinical evidence for GSP’s efficacy in modulating the lipolysis pathway, especially in regards to weight and body fat reduction, in post-menopausal overweight and class I obese women. For the first time, the mechanism of action of GSP on increased basal metabolic rate is supported by company clinical data, strengthening GSP’s biomedical profile.  

    Click here for the link to the published research

    References
    1 Di Pierro F., et al., Alternative Medicine Review. Volume 14, Number 2 (2009).
    2 Pietta P.G., et al., Biochem. Mol. Biol. Intl. 46: 895-903 (1998).
    3 Simonetti P., et al., 16th International Congress of Nutrition. July August, Montreal, Canada (1997).
    4 Belcaro et al., Evid Based Complement Alternat Med. Volume 2013:869061 (2103).